Last update Jan. 27, 2021
Likely Compatibility
We do not have alternatives for C3160 H4848 N898 O881 S12.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C3160 H4848 N898 O881 S12 is Laronidase in Molecular formula.
Is written in other languages:C3160 H4848 N898 O881 S12 is also known as
C3160 H4848 N898 O881 S12 belongs to this group or family:
Main tradenames from several countries containing C3160 H4848 N898 O881 S12 in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | ≈ 0 | % |
Molecular weight | 69.900 - 83.000 | daltons |
VD | 0.6 | l/Kg |
T½ | 1.5 - 3.6 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Recombinant-type of alfa-L-iduronidase that is used in enzyme replacement therapy in patients with Mucopolysaccharidosis I (MPS I).
Intravenous administration once a week.
Its high molecular weight explains the null passage observed in the milk of a nursing mother who had received weekly doses of Laronidase for three months, while she was breastfeeding. No physical or developmental problems in infants in the short or long term were observed (Castorina 2015).
Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant plasma.